324 related articles for article (PubMed ID: 33972144)
1. Correlation between outcome and extent of residual disease in the sentinel node after neoadjuvant chemotherapy in clinically fine-needle proven node-positive breast cancer patients.
Canavese G; Tinterri C; Carli F; Garrone E; Spinaci S; Della Valle A; Barbieri E; Marrazzo E; Bruzzi P; Dozin B
Eur J Surg Oncol; 2021 Aug; 47(8):1920-1927. PubMed ID: 33972144
[TBL] [Abstract][Full Text] [Related]
2. Improved False-Negative Rates with Intraoperative Identification of Clipped Nodes in Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy.
Cabıoğlu N; Karanlık H; Kangal D; Özkurt E; Öner G; Sezen F; Yılmaz R; Tükenmez M; Önder S; İğci A; Özmen V; Dinççağ A; Engin G; Müslümanoğlu M
Ann Surg Oncol; 2018 Oct; 25(10):3030-3036. PubMed ID: 29978371
[TBL] [Abstract][Full Text] [Related]
3. Impact of completion axillary lymph node dissection in patients with breast cancer and isolated tumour cells or micrometastases in sentinel nodes.
Houvenaeghel G; Boher JM; Reyal F; Cohen M; Garbay JR; Classe JM; Rouzier R; Giard S; Faure C; Charitansky H; Tunon de Lara C; Daraï E; Hudry D; Azuar P; Gimbergues P; Villet R; Sfumato P; Lambaudie E
Eur J Cancer; 2016 Nov; 67():106-118. PubMed ID: 27640137
[TBL] [Abstract][Full Text] [Related]
4. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy.
Rebollo-Aguirre AC; Gallego-Peinado M; Menjón-Beltrán S; García-García J; Pastor-Pons E; Chamorro-Santos CE; Ramos-Font C; Salamanca-Ballesteros A; Llamas-Elvira JM; Olea-Serrano N
Rev Esp Med Nucl Imagen Mol; 2012; 31(3):117-23. PubMed ID: 21676504
[TBL] [Abstract][Full Text] [Related]
5. Does Lymph Node Status Prior to Neoadjuvant Chemotherapy Influence the Number of Sentinel Nodes Removed?
Baker JL; Muhsen S; Zabor EC; Stempel M; Gemignani ML
Ann Surg Oncol; 2019 Feb; 26(2):336-342. PubMed ID: 30506175
[TBL] [Abstract][Full Text] [Related]
6. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation.
Newman EA; Sabel MS; Nees AV; Schott A; Diehl KM; Cimmino VM; Chang AE; Kleer C; Hayes DF; Newman LA
Ann Surg Oncol; 2007 Oct; 14(10):2946-52. PubMed ID: 17514407
[TBL] [Abstract][Full Text] [Related]
7. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Laws A; Hughes ME; Hu J; Barry WT; Dominici L; Nakhlis F; Barbie T; Duggan M; Weiss A; Rhei E; Carter K; Nimbkar S; Schnitt SJ; King TA
Ann Surg Oncol; 2019 Nov; 26(12):3846-3855. PubMed ID: 31222687
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of sentinel lymph node micrometastases in patients with invasive breast carcinoma.
Cipolla C; Graceffa G; La Mendola R; Fricano S; Fricano M; Vieni S
Ann Ital Chir; 2015; 86():497-502. PubMed ID: 26898168
[TBL] [Abstract][Full Text] [Related]
9. Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).
Boughey JC; Ballman KV; Le-Petross HT; McCall LM; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Feliberti EC; Hunt KK
Ann Surg; 2016 Apr; 263(4):802-7. PubMed ID: 26649589
[TBL] [Abstract][Full Text] [Related]
10. The significance of sentinel lymph node micrometastasis in breast cancer: Comparing outcomes with and without axillary clearance.
Youssef MMG; Cameron D; Pucher PH; Olsen S; Ferguson D
Breast; 2016 Dec; 30():101-104. PubMed ID: 27668857
[TBL] [Abstract][Full Text] [Related]
11. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.
Kuehn T; Bauerfeind I; Fehm T; Fleige B; Hausschild M; Helms G; Lebeau A; Liedtke C; von Minckwitz G; Nekljudova V; Schmatloch S; Schrenk P; Staebler A; Untch M
Lancet Oncol; 2013 Jun; 14(7):609-18. PubMed ID: 23683750
[TBL] [Abstract][Full Text] [Related]
12. Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy.
Cohen LF; Breslin TM; Kuerer HM; Ross MI; Hunt KK; Sahin AA
Am J Surg Pathol; 2000 Sep; 24(9):1266-72. PubMed ID: 10976701
[TBL] [Abstract][Full Text] [Related]
13. Axillary Staging After Neoadjuvant Chemotherapy for Breast Cancer: A Pilot Study Combining Sentinel Lymph Node Biopsy with Radioactive Seed Localization of Pre-treatment Positive Axillary Lymph Nodes.
Diego EJ; McAuliffe PF; Soran A; McGuire KP; Johnson RR; Bonaventura M; Ahrendt GM
Ann Surg Oncol; 2016 May; 23(5):1549-53. PubMed ID: 26727919
[TBL] [Abstract][Full Text] [Related]
14. Is Clinical Exam of the Axilla Sufficient to Select Node-Positive Patients Who Downstage After NAC for SLNB? A Comparison of the Accuracy of Clinical Exam Versus MRI.
Moo TA; Jochelson MS; Zabor EC; Stempel M; Raiss M; Mamtani A; Tadros AB; El-Tamer M; Morrow M
Ann Surg Oncol; 2019 Dec; 26(13):4238-4243. PubMed ID: 31583546
[TBL] [Abstract][Full Text] [Related]
15. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
16. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation.
Gimbergues P; Abrial C; Durando X; Le Bouedec G; Cachin F; Penault-Llorca F; Mouret-Reynier MA; Kwiatkowski F; Maublant J; Tchirkov A; Dauplat J
Ann Surg Oncol; 2008 May; 15(5):1316-21. PubMed ID: 18311507
[TBL] [Abstract][Full Text] [Related]
17. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer.
Alvarado R; Yi M; Le-Petross H; Gilcrease M; Mittendorf EA; Bedrosian I; Hwang RF; Caudle AS; Babiera GV; Akins JS; Kuerer HM; Hunt KK
Ann Surg Oncol; 2012 Oct; 19(10):3177-84. PubMed ID: 22772869
[TBL] [Abstract][Full Text] [Related]
18. Sentinel lymph node biopsy after neoadjuvant chemotherapy in a patient with operable breast cancer.
Hino M; Sano M; Sato N; Homma K
Surg Today; 2008; 38(7):585-91. PubMed ID: 18612781
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy.
Khan A; Sabel MS; Nees A; Diehl KM; Cimmino VM; Kleer CG; Schott AF; Hayes DF; Chang AE; Newman LA
Ann Surg Oncol; 2005 Sep; 12(9):697-704. PubMed ID: 16079956
[TBL] [Abstract][Full Text] [Related]
20. Favorable outcome with sentinel lymph node biopsy alone after neoadjuvant chemotherapy in clinically node positive breast cancer at diagnosis: Turkish Multicentric NEOSENTI-TURK MF-18-02-study.
Cabıoğlu N; Karanlık H; Yıldırım N; Müslümanoğlu M; Çakmak Karadeniz G; Trabulus Can D; Tükenmez M; Ersoy YE; Uras C; Zengel B; Emiroğlu S; Polat AK; Yeniay L; Özkurt E; Kara H; İbiş K; Aydıner A; Özmen V; İğci A
Eur J Surg Oncol; 2021 Oct; 47(10):2506-2514. PubMed ID: 34217580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
